New dosing strategy aims to keep myeloma patients out of the hospital

NCT ID NCT06421675

Recruiting now Disease control Sponsor: Ontario Clinical Oncology Group (OCOG) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new way of giving the drug elranatamab to people with multiple myeloma that has come back or stopped responding to other treatments. The goal is to see if giving the drug less often and outside the hospital can reduce side effects and hospital stays. About 40 adults who have already tried at least three other types of treatment will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytokine release syndrome plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Juravinski Cancer Center
RECRUITING

Hamilton, Ontario, L8V 1C3, Canada
Kingston General Hospital
RECRUITING

Kingston, Ontario, K7L 2V7, Canada
London Health Science Centre - Victoria Hospital
RECRUITING

London, Ontario, N6A 5W9, Canada
London Health Science Centre - Victoria Hospital
RECRUITING

London, Ontario, N6A 5W9, Canada
Ottawa Hospital
RECRUITING

Ottawa, Ontario, K1H 8L6, Canada
Vancouver Cancer Center
RECRUITING

Vancouver, British Columbia, V5Z 1L3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.